Iclusig (Ponatinib)

What Is Iclusig and What Is It Used For?

Iclusig (ponatinib) is a targeted cancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. It is used to treat adults with chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) when other TKI treatments have failed or when the T315I resistance mutation is present.

Chronic myeloid leukaemia is a type of blood cancer characterised by the uncontrolled production of abnormal white blood cells in the bone marrow. In nearly all cases of CML, a genetic abnormality known as the Philadelphia chromosome is present. This chromosome results from a translocation between chromosomes 9 and 22, creating the BCR-ABL fusion gene. The BCR-ABL oncoprotein produced by this gene acts as a constitutively active tyrosine kinase, sending continuous signals that drive the uncontrolled proliferation of leukaemia cells.

Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) is a particularly aggressive form of leukaemia that also harbours the Philadelphia chromosome. In this type of leukaemia, excessive numbers of immature white blood cells (lymphoblasts) accumulate in the blood and bone marrow, crowding out normal blood cell production. Ph+ ALL accounts for approximately 20–30% of adult ALL cases and has historically been associated with a poor prognosis.

Ponatinib was specifically designed to inhibit the BCR-ABL oncoprotein, including its most treatment-resistant form carrying the T315I mutation. This single amino acid substitution at the gatekeeper residue of BCR-ABL creates a steric clash that prevents all other approved TKIs (imatinib, dasatinib, nilotinib, and bosutinib) from binding effectively. By using a unique carbon–carbon triple bond linker in its molecular structure, ponatinib can accommodate this mutation and maintain potent inhibitory activity.

Iclusig is approved for use in adults who meet one of the following criteria: patients with CML in any phase (chronic, accelerated, or blast crisis) for whom no other TKI therapy is appropriate, or patients with Ph+ ALL for whom no other TKI therapy is appropriate. It is also indicated specifically for patients whose leukaemia carries the T315I mutation, regardless of prior treatment history. The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have both approved ponatinib based on pivotal clinical trial data demonstrating significant and durable responses in these difficult-to-treat patient populations.

What Should You Know Before Taking Iclusig?

Before starting Iclusig, your doctor will assess your cardiovascular health, liver function, and pancreatic enzyme levels. There are several important contraindications, warnings, and precautions that both patients and healthcare providers must be aware of.

Contraindications

Do not take Iclusig if you are allergic to ponatinib or any of the other ingredients in the tablets. The inactive ingredients include lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate, talc, macrogol 4000, polyvinyl alcohol, and titanium dioxide (E171). If you have a known hypersensitivity to any of these components, inform your doctor before starting treatment.

Warnings and Precautions

Iclusig carries several serious warnings that require careful medical monitoring. Before and during treatment, your healthcare team will perform regular assessments to detect potential complications early. It is essential that you inform your doctor about your complete medical history, including any of the following conditions:

• Liver disease or impaired liver function: Hepatotoxicity has been reported with ponatinib. Liver function tests will be performed regularly throughout treatment
• Pancreatic disease: Pancreatitis is a known serious adverse effect. Serum lipase levels will be monitored every two weeks during the first two months and periodically thereafter
• Impaired kidney function: Dose adjustments or additional monitoring may be required
• History of heart attack or stroke: Arterial occlusive events are among the most serious risks of Iclusig treatment
• History of blood clots: Both arterial and venous thrombotic events have been reported
• Renal artery stenosis: Narrowing of the blood vessels to the kidneys has been observed
• Heart problems: Including heart failure, irregular heartbeat, and QT prolongation
• High blood pressure: Hypertension may worsen during treatment
• Aneurysm or vessel wall tear: Patients with a history of or risk factors for these conditions require special consideration
• Bleeding disorders: Iclusig can affect blood cell counts and coagulation
• Hepatitis B infection: Reactivation of hepatitis B has been reported with Iclusig, which can be fatal in some cases. Patients will be screened for hepatitis B before starting treatment
• Alcohol misuse: This may increase the risk of pancreatic and hepatic complications

Your doctor will perform the following assessments before and during treatment:

• Cardiovascular assessment: Evaluation of heart function and arterial and venous health
• Complete blood count: Repeated every two weeks for the first three months, then monthly or as directed
• Serum lipase monitoring: Every two weeks for the first two months, then periodically. Treatment may be interrupted or the dose reduced if lipase levels are elevated
• Liver function tests: Performed regularly throughout treatment as directed by your doctor

A brain condition called posterior reversible encephalopathy syndrome (PRES) has been reported in patients treated with ponatinib. Symptoms include sudden severe headache, confusion, seizures, and visual changes. Contact your doctor immediately if you experience any of these symptoms during treatment, as this condition can be serious.

Children and Adolescents

Iclusig is not recommended for use in patients under 18 years of age. There is insufficient clinical data on the safety and efficacy of ponatinib in the paediatric population. Treatment of CML and Ph+ ALL in children follows different protocols and involves alternative therapeutic agents.

Pregnancy and Breastfeeding

Iclusig may cause harm to an unborn baby. Women of childbearing potential must use effective contraception during treatment with Iclusig. Men taking Iclusig are also advised not to father children during treatment. If you are pregnant or suspect you may be pregnant, inform your doctor immediately. Iclusig should only be used during pregnancy if the potential benefit is considered to outweigh the risk to the foetus, and only under strict medical supervision.

Breastfeeding must be discontinued during treatment with Iclusig. It is not known whether ponatinib passes into breast milk. Given the potential for serious adverse reactions in nursing infants, mothers must choose between breastfeeding and receiving Iclusig treatment.

Driving and Operating Machinery

Exercise caution when driving or using machinery while taking Iclusig. Side effects such as visual disturbances, dizziness, drowsiness, and fatigue have been reported and may impair your ability to drive or operate machinery safely.

Lactose Content

Iclusig tablets contain lactose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine.

How Does Iclusig Interact with Other Drugs?

Ponatinib is metabolised primarily by the CYP3A4 enzyme system and is also a substrate for and inhibitor of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). This means that many commonly used medications can either increase or decrease ponatinib levels in the blood, and ponatinib can likewise affect the levels of other drugs.

It is essential to inform your doctor, pharmacist, or specialist nurse about all medications you are currently taking, have recently taken, or might take. This includes prescription medicines, over-the-counter drugs, and herbal or dietary supplements. Some drug interactions with Iclusig can be clinically significant and may require dose adjustments, additional monitoring, or avoidance of certain combinations.

Major Interactions – CYP3A4 Inhibitors (Increase Ponatinib Levels)

Strong CYP3A4 inhibitors can significantly increase ponatinib plasma concentrations, raising the risk of toxicity. These medications slow down the breakdown of ponatinib in the body, leading to higher and more prolonged exposure. Your doctor may need to reduce your Iclusig dose or consider alternative medications if co-administration is necessary.

Major Interactions – CYP3A4 Inducers (Decrease Ponatinib Levels)

Strong CYP3A4 inducers can significantly reduce ponatinib blood levels, potentially compromising treatment efficacy. These medications speed up the metabolism of ponatinib, leading to lower exposure. Alternative therapies should be considered where possible.

Drugs Affected by Ponatinib

Ponatinib can also affect the blood levels of other medications you may be taking. As an inhibitor of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), ponatinib can increase the plasma concentrations of substrates of these transporters. The following drugs may require monitoring or dose adjustments when used concurrently with Iclusig:

• Digoxin (heart failure medication) – P-gp substrate; levels may increase
• Dabigatran (anticoagulant) – P-gp substrate; increased bleeding risk
• Colchicine (gout medication) – P-gp substrate; increased toxicity risk
• Pravastatin, Rosuvastatin (cholesterol-lowering drugs) – BCRP substrates; levels may increase
• Methotrexate (cancer/autoimmune drug) – BCRP substrate; increased toxicity risk
• Sulfasalazine (anti-inflammatory) – BCRP substrate; levels may increase

What Is the Correct Dosage of Iclusig?

The recommended starting dose of Iclusig is 45 mg taken once daily as a film-coated tablet. Your doctor may reduce the dose based on your treatment response, side effects, or blood test results. Iclusig must always be taken exactly as prescribed by your specialist.

Iclusig treatment should only be initiated by a physician experienced in the diagnosis and management of leukaemia. The dosage is individualised based on clinical response, tolerability, and disease characteristics. The three available tablet strengths (15 mg, 30 mg, and 45 mg) allow for flexible dose adjustments throughout the course of treatment.

Adults

Your doctor may reduce your dose or temporarily stop Iclusig in the following situations:

• An adequate treatment response has been achieved
• The number of white blood cells called neutrophils decreases significantly (neutropenia)
• Platelet counts decrease (thrombocytopenia)
• A serious non-haematological side effect develops
• Inflammation of the pancreas (pancreatitis) occurs
• Elevated levels of serum lipase or amylase are detected in blood tests
• Heart or blood vessel problems develop
• Liver disease is present or worsens

Children and Adolescents

Iclusig is not approved for use in children and adolescents under 18 years of age. There are no clinical data supporting its use in this population. Paediatric patients with CML or Ph+ ALL should be managed according to age-appropriate treatment protocols under specialist supervision.

Elderly Patients

No specific dose adjustment is recommended for elderly patients based on age alone. However, older patients may be at increased risk of cardiovascular events and other adverse effects. The treating physician will assess the benefit–risk balance carefully and may initiate treatment at a lower dose or implement more frequent monitoring in this population.

Missed Dose

If you forget to take a dose of Iclusig, take the next dose at the usual time. Do not take a double dose to make up for a missed dose. If you miss doses regularly, speak with your healthcare team, as consistent dosing is important for maintaining therapeutic drug levels and treatment effectiveness.

Overdose

If you take more than the prescribed amount of Iclusig, contact your doctor or seek medical attention immediately. There is no specific antidote for ponatinib overdose. Treatment is supportive and based on symptoms. Medical professionals will monitor your vital signs, blood counts, and organ function closely.

What Are the Side Effects of Iclusig?

Like all medicines, Iclusig can cause side effects, although not everybody gets them. Patients over 65 years of age are more likely to experience side effects. Some side effects are serious and require immediate medical attention.

The side effects of ponatinib are categorised below by how commonly they occur. Your treating specialist will discuss the expected side effect profile with you before starting treatment and will perform regular monitoring to detect complications early. It is important to report any new or worsening symptoms to your healthcare team promptly.

If you experience any side effects, including those not listed above, tell your doctor, pharmacist, or specialist nurse. Reporting suspected adverse reactions helps with ongoing monitoring of the benefit–risk balance of this medicine. You can report side effects to your national pharmacovigilance authority.

How Should You Store Iclusig?

Store Iclusig in the original packaging, protected from light, and out of the sight and reach of children. Do not use after the expiry date printed on the bottle label and carton.

Proper storage of Iclusig is essential to maintain the quality and effectiveness of the medication. The film-coated tablets are supplied in plastic bottles that contain a sealed plastic container of desiccant (molecular sieve). This desiccant absorbs moisture and helps keep the tablets dry. Follow these storage instructions carefully:

• Keep in the original packaging to protect from light
• Do not remove the desiccant container from the bottle – and do not swallow it
• Keep the bottle tightly closed when not in use
• Check the expiry date on the bottle label and carton; do not use after the last day of the stated month
• Keep out of the sight and reach of children

Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment and ensure safe handling of pharmaceutical products.

What Does Iclusig Contain?

The active substance in Iclusig is ponatinib (as ponatinib hydrochloride). Each tablet contains either 15 mg, 30 mg, or 45 mg of ponatinib. The tablets are white, round, biconvex film-coated tablets.

Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific excipients. Iclusig tablets contain the following components:

Active Ingredient

• Ponatinib (as ponatinib hydrochloride) – 15 mg, 30 mg, or 45 mg per tablet

Inactive Ingredients (Excipients)

• Lactose monohydrate
• Microcrystalline cellulose
• Sodium starch glycolate
• Colloidal anhydrous silica
• Magnesium stearate
• Talc
• Macrogol 4000
• Polyvinyl alcohol
• Titanium dioxide (E171)

Tablet Identification

Not all pack sizes may be marketed in all countries. Iclusig is manufactured by Incyte Biosciences Distribution B.V. (Amsterdam, Netherlands) and Tjoapack Netherlands B.V. (Etten-Leur, Netherlands). The marketing authorisation holder is Incyte Biosciences Distribution B.V., Paasheuvelweg 25, 1105 BP Amsterdam, Netherlands.

How Does Iclusig Work?

Iclusig works by blocking the BCR-ABL tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome that drives the uncontrolled growth of leukaemia cells. Ponatinib is uniquely designed to overcome the T315I resistance mutation that renders all other approved TKIs ineffective.

To understand how Iclusig works, it helps to understand the biology of the diseases it treats. In both CML and Ph+ ALL, a genetic accident called the Philadelphia chromosome translocation creates a fusion gene called BCR-ABL. This gene produces a constitutively active tyrosine kinase enzyme – a molecular switch that is permanently stuck in the “on” position. This signal tells the bone marrow to produce excessive numbers of abnormal white blood cells.

First-generation TKIs such as imatinib (Gleevec/Glivec) revolutionised CML treatment by blocking the BCR-ABL kinase. However, some patients develop resistance through mutations in the BCR-ABL gene that prevent imatinib from binding effectively. Second-generation TKIs (dasatinib, nilotinib, bosutinib) were developed to overcome many of these resistance mutations, but none of them can overcome the T315I “gatekeeper” mutation.

Ponatinib was rationally designed using computational chemistry and structure-based drug design to accommodate the bulky isoleucine residue at position 315 that blocks all other TKIs. Its molecular structure features a unique ethynyl (carbon–carbon triple bond) linkage that allows it to avoid the steric clash with the mutant gatekeeper residue. This gives ponatinib potent activity against native BCR-ABL and all known single-mutation resistance variants, including T315I.

In addition to BCR-ABL, ponatinib also inhibits several other kinases involved in cancer cell signalling, including members of the VEGFR, PDGFR, FGFR, EPH receptor, SRC, KIT, RET, TIE2, and FLT3 kinase families. This broad kinase inhibition profile contributes to its anticancer activity but also underlies some of its toxicity, particularly the cardiovascular side effects associated with VEGFR inhibition.

The clinical efficacy of ponatinib was demonstrated in the pivotal PACE (Ponatinib Ph+ ALL and CML Evaluation) trial, which enrolled patients with CML and Ph+ ALL who were resistant or intolerant to dasatinib or nilotinib, or who had the T315I mutation. The study showed major cytogenetic responses in 56% of chronic-phase CML patients and significant haematologic responses in patients with advanced disease.